Novo Nordisk

News

Novo Nordisk has launched an audacious bid to elope with weight-loss therapy developer Metsera, before it can go ahead with a marriage to Pfizer.

News

Novo Nordisk's chairman Helge Lund will step down next month under pressure from the group's controlling shareholder, the Novo Nordisk Foundation.

News

Novo Nordisk has boosted its pipeline by paying $340m upfront for rights to an Omeros drug for PNH and other rare blood and kidney disorders.

News

Novo Nordisk has agreed to buy Akero and its MASH drug efruxifermin for $4.7bn upfront, soon after Wegovy was approved for the common liver disease.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

R&D

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.